Initiating the antiretroviral therapy in treatment-naïve patients Schemes with 2 NRTIs+PIs were preferred (137 patients; 56.38%) followed by those with 2 NRTIs+NNRTIs (80 patients; 32.92%), 2 NRTIs+IIs (15 patients; 6.17%) and other schemes (11 patients; 6.17%). The choice of the ARV regimen was not influenced by age, gender, route of transmission and RNA-HIV1 at baseline. There were no statistically significant differences in the CD4 cell count increase at 6 and 12 months of therapy, or in the percentage of patients with undetectable RNA-HIV1 after 6 months of treatment. The percentage of patients with VL undetectable at 6 months was 51.06% for those treated with NNRTIs, 34.29% for those treated with PIs, 30.7% for those treated with IIs and 20% for those treated with other regimens. These values reflect the important issues of adherence to ARV therapy seen in our patients.
Conclusion
In our patients a CD4 cell count below 350 cells/cmm and co-infections influence the choice of the ARV regimen. Inadequate adherence is responsible for the small percentage of patients with VL undetectable after 6 months of treatment.
